Back to search

Duquesne

EVALUATING SEX DIFFERENCES IN THE NEUROIMMUNE RESPONSE FOLLOWING NEUROINFLAMMATION AND RELIEF DUE TO NANOTHERANOSTIC TREATMENT

Abstract

dc:description.abstract

Until recently, the majority of preclinical neuroinflammatory studies were performed on males. Because of this, less is known about the female neuroinflammatory response to injury, formation of pain, or response to pain-relieving therapies. The neuroinflammatory response is multifaceted with neuronal, glial, and immune cells all contributing to the induction and resolution of neuroinflammation. During this response, macrophages typically undergo an upregulation of cyclooxygenase-2 (COX-2) leading to the production of prostaglandin E2 (PGE2), which is linked to neuronal sensitization and pain. Non-steroidal anti-inflammatory drugs (NSAIDs) attenuate PGE2 by the inhibition of COX-2. A limitation with NSAIDs is that due to the systemic dosage needed to achieve neuropathic pain relief there are risks of off-target toxicity. In collaboration with the Janjic Lab, a novel COX-2 inhibiting theranostic nanoemulsion has been seen to alleviate mechanical hypersensitivity in male rats who have undergone chronic constriction injury (CCI); however, how it works to alleviate female neuropathic pain remained unknown. This study evaluated the efficacy of 1X CXB-NE (0.24 mg/kg) in relieving neuropathic hypersensitivity and saw that females experienced less relief. Increasing the concentration to 10X CXB-NE (2.4 mg/kg) resolved this sex difference with equivalent relief being observed. Knowing the therapeutic works differently in females than in males, we furthered our understanding by transcriptionally evaluating the sex differences during neuroinflammation and relief. Here we found that how males and females responded to treatment was unique. Following neuroinflammatory induction, both sexes had an upregulation of a CREB binding protein, activating transcription factor 3 (ATF-3); following 10X CXB-NE treatment, which only females had a significant down regulation of this gene. Interestingly, it has been seen that ATF-3 is a transcriptional regulator to the COX-2 expression. Males on the other hand appear to have an upregulation of neutrophil involvement, specifically with S1008A and S1009A, which are markers for the release of neutrophil extracellular traps. This body of work shows for the first time that female neuropathic pain can be relieved using a COX-2 inhibiting theranostic nanoemulsion treatment, and that how COX-2 inhibition provides relief is different in males and females.

Degree

thesis:*
Name thesis:degree_name
PhD
Level thesis:degree_level
One-year Embargo
Discipline thesis:degree_discipline
Biological Sciences

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Deal, Brooke
Contributors dc:contributor
  • John Pollock
  • Jelena Janjic
  • Jan Janecka
  • Lauren O'Donnell
  • Jill Dembowski

Subjects

dc:subject × 11

Rights

Language dc:language
English

Identifiers

dc:identifier.*
Repository record dc:identifier
https://dsc.duq.edu/etd/2253

Chain of custody

source
Harvested from
Duquesne
Base URL
dsc.duq.edu/do/oai/
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
citation

Deal, Brooke. EVALUATING SEX DIFFERENCES IN THE NEUROIMMUNE RESPONSE FOLLOWING NEUROINFLAMMATION AND RELIEF DUE TO NANOTHERANOSTIC TREATMENT. One-year Embargo thesis, https://dsc.duq.edu/etd/2253